How to Identify and Control Genotoxic Impurities
Add bookmark
How to Identify and Control Genotoxic Impurities
Add bookmark
Dr. Andrew Teasdale, Senior QA Executive at AstraZeneca, joins Helen Winsor from Pharma IQ, to discuss genotoxicity and carcinogenicity testing. He begins by summing up the challenges that exist with interpreting the regulatory guidelines, and discusses how people in the industry can overcome these hurdles to accurately interpret the guidelines. The interview also covers the proposed harmonised guidelines from the ICH and whether these might solve the problems. [inlinead]
Tags:
Andrew Teasdale
genotoxicity and carcinogenicity testing
carcinogenicity testing
genotoxicity
ICH
regulatory guidelines
genotoxic impurities
